The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Strategy Implementation Review

24 Mar 2021 07:00

Arix Bioscience PLC (ARIX) Strategy Implementation Review 24-March-2021 / 07:00 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


 

Arix Bioscience plc

 

("Arix" or "the Company")

 

Strategy Implementation Review

 

LONDON, 24 March 2021: The board of Arix (LSE: ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces the commencement of a strategy implementation review (the "Review").

 

Arix collaborates with exceptional entrepreneurs and provides the capital, expertise and global networks needed to help accelerate their ideas into important new treatments. As a listed company, Arix is able to bring this exciting growth phase to a broader range of investors. The Company is committed to its strategy of supporting its current portfolio and investing in the next wave of opportunities, deploying its £174m capital pool. Arix will continue to seek out and support a mix of late- and early-stage investment opportunities, on an approximate ratio of 2:1 in order to manage risk and optimise returns.

 

In 2020 NAV increased by 62% to £328m vs the year-end 2023 NAV target of £500m, net operating costs reduced by over 35% and a new Scientific Advisory Board was appointed.

 

As previously stated, Arix is committed to a programme of stronger corporate governance as well as the expansion of its investment team in the UK and US to take advantage of a strong pipeline of new opportunities.

 

The Review will examine:

Board composition, ensuring that the Company's governance reflects best practice and has the right mix of skills and experience; Executive resourcing, choosing the right mix of skills and experience to deploy capital into the Company's exciting pipeline of new opportunities; and Remuneration structures, enabling Arix to attract and retain the right talent for the business.

 

As part of the Review, the Company will solicit views from a wide range of stakeholders. This will include a shareholder consultation to fully understand the views of all shareholders and reflect their wishes as the Company's owners. This programme of work will be overseen on the Board's behalf by the Company's Senior Independent Director, Giles Kerr, and has already begun through engagement with the Company's largest shareholder.

 

The initial findings of the Review will be delivered ahead of the notice to shareholders of the forthcoming AGM, which is expected to be circulated on or around 23 April.

 

Commenting on the Review, Arix's Chairman, Naseem Amin, said:

 

"The Company's founding thesis continues to be sound and has been validated by the VelosBio exit. As a consequence, we believe it is necessary to accelerate the development of our capabilities to ensure we make the most of the opportunities before us.

 

"We aim to report the Review's initial findings in time for the 2021 AGM and welcome constructive engagement from all those with whom we have a relationship, as we work to ensure Arix offers a high quality platform to identify and support exciting new biotech opportunities."

 

[ENDS]

 

For more information, please contact:

 

Arix Bioscience plcCharlotte Parry, Head of Investor Relations+44 (0)20 7290 1072charlotte@arixbioscience.com

 

Montfort CommunicationsOlly Scott

+44(0)78 1234 5205

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com  

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 


ISIN:GB00BD045071
Category Code:MSCU
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:96104
EQS News ID:1177832
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
7th Feb 202411:30 amEQSTransaction Update
29th Jan 202412:15 pmEQSResults of First General Meeting
24th Jan 20245:30 pmEQSHolding(s) in Company
24th Jan 20245:30 pmEQSHolding(s) in Company
23rd Jan 20247:00 amEQSUpdate on the Scheme and Publication of Notice of Second General Meeting
22nd Jan 20247:00 amEQSUpdate on the Scheme and Resignation of Directors
19th Jan 20247:01 amEQSFinancial update on Harpoon Therapeutics acquisition by Merck (MSD)
19th Jan 20247:00 amEQSUnaudited NAV for December 2023
8th Jan 20245:15 pmEQSPortfolio company Harpoon Therapeutics to be acquired by Merck (MSD)
5th Jan 20247:00 amEQSPublication of Circular and RTW Bio Prospectus
4th Jan 20245:30 pmEQSHolding(s) in Company
22nd Dec 202311:00 amEQSUpdate regarding timing of Proposed Scheme of Reconstruction
13th Dec 20237:00 amEQSUnaudited NAV for November 2023
8th Dec 20237:00 amEQSPortfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial
13th Nov 20234:00 pmEQSCorrection: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
10th Nov 20238:00 amEQSPortfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock
10th Nov 20237:00 amEQSPDMR Notification & Director Shareholding
8th Nov 20237:05 amEQSUnaudited NAV for October 2023
3rd Nov 20234:30 pmEQSPDMR Notification & Director Shareholding
2nd Nov 20236:20 pmEQSPDMR Notification & Director Shareholding
1st Nov 20234:30 pmEQSPortfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102
1st Nov 20237:06 amRNSRTW Biotech to acquire Arix Bioscience's assets
24th Oct 20237:00 amEQSPortfolio company Harpoon Therapeutics announces up to $150 million private placement
6th Oct 20237:00 amEQSUnaudited NAV for September 2023
27th Sep 20237:01 amEQSInterim Results for the Six Months Ended 30 June 2023
27th Sep 20237:00 amEQSBoard Change
14th Sep 20237:01 amEQSNotice of Results and Investor Presentation
14th Sep 20237:00 amEQSUnaudited NAV for August 2023
7th Aug 20237:00 amEQSUnaudited NAV for July 2023
17th Jul 20233:00 pmEQSHolding(s) in Company
13th Jul 20237:01 amEQSArix Announces Strategic Review
13th Jul 20237:00 amEQSUnaudited NAV for June 2023
23rd Jun 20232:04 pmEQSPortfolio company Disc Medicine raises $157.8 million in public offering
9th Jun 20232:53 pmEQSPortfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA
9th Jun 20237:00 amEQSUnaudited NAV for May 2023
31st May 202311:51 amRNSDirector/PDMR Shareholding
24th May 20237:00 amEQSCorrection: Result of Annual General Meeting
23rd May 20234:30 pmEQSResult of Annual General Meeting
16th May 20234:36 pmEQSPortfolio company Ensoma announces closing of Series B Extension
12th May 20237:00 amEQSUnaudited NAV for April 2023
5th May 20234:30 pmRNSTotal Voting Rights
4th May 20235:02 pmRNSDirector/PDMR Shareholding
4th May 202312:15 pmRNSDirector/PDMR Shareholding
2nd May 20233:52 pmRNSDirector/PDMR Shareholding
27th Apr 20237:00 amEQSArix Co-leads $50 Million Series B Financing for New Portfolio Company Evommune
25th Apr 20237:03 amEQSFinancial Results for the Year Ended 31 December 2022, Publication of Annual Report & Notice of AGM
19th Apr 20231:30 pmEQSFull Year results now to be released on 25 April 2023
17th Apr 20237:00 amEQSUnaudited NAV for March 2023
14th Apr 202312:00 pmEQSNotice of Results and Investor Presentation
28th Mar 20237:00 amEQSPortfolio company Harpoon Therapeutics announces closing of $25 million private placement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.